^
Association details:
| Biomarker: | BRCA1 mutation |
|---|---|
| Cancer: | Breast Cancer |
| Drug: | Lynparza (olaparib) (PARP inhibitor) + VIO-01 (PARP1 inhibitor, KU70/KU80 inhibitor, MRN complex inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
18P - PARP1 trapping and hyperactivation by the decoy agonist OX425 induces DNA repair abrogation and a robust anti-tumor immune response
Published date:
03/02/2023
Excerpt:
Importantly, OX425 treatment significantly delayed acquired resistance to olaparib in BRCA1 mutated MDA-MB-436 cell-derived xenografts.
